GAL10 Antibody

What is the GAL10 protein and what are its key characteristics?

Galectin-10 (GAL10), also known as Charcot-Leyden crystal protein (CLC), is a human protein that regulates immune responses through the recognition of cell-surface glycans. It is essential for the anergy and suppressive function of CD25-positive regulatory T-cells (Treg) . The human GAL10 protein has a canonical amino acid length of 142 residues (specifically Ser2-Arg142) and a molecular mass of approximately 16.5 kilodaltons . The protein is primarily localized in the cytoplasm and is notably expressed in immune-related tissues including the tonsil, spleen, lymph node, and bone marrow . GAL10 is encoded by the CLC gene, which may also be referred to as LGALS10 or LGALS10A in scientific literature .

One of the most distinctive characteristics of GAL10 is its ability to form crystals, known as Charcot-Leyden crystals (CLCs), which play a significant role in type 2 immune responses and have been implicated in asthma pathophysiology .

What experimental applications are GAL10 antibodies commonly used for?

GAL10 antibodies are versatile tools in immunological research with applications across multiple experimental techniques:

For optimal results, researchers should determine appropriate dilutions for each specific application, as sensitivity and specificity can vary between experimental systems .

How should GAL10 antibodies be stored and reconstituted for maximum stability?

Proper storage and reconstitution of GAL10 antibodies are critical for maintaining their activity and specificity over time:

For long-term storage:

• Use a manual defrost freezer and avoid repeated freeze-thaw cycles

• Store at -20 to -70°C for up to 12 months from the date of receipt in the original shipping container

For reconstitution:

• Reconstitute lyophilized antibodies in sterile PBS to a final concentration of 0.5 mg/mL

• After reconstitution, the antibody can be stored at 2-8°C under sterile conditions for approximately 1 month

• For extended storage after reconstitution, aliquot and store at -20 to -70°C under sterile conditions for up to 6 months

To minimize performance degradation, limit exposure to room temperature and avoid repeated freeze-thaw cycles by preparing working aliquots. Always centrifuge vials briefly before opening to ensure recovery of all material, particularly after thawing .

How do crystalline forms of GAL10 influence immune responses, and how can anti-GAL10 antibodies modulate these effects?

GAL10 crystallization has significant immunological consequences with direct implications for allergic diseases:

GAL10 proteins can spontaneously form Charcot-Leyden crystals (CLCs) that act as potent type 2 immunity adjuvants. Research has demonstrated that when administered to mice, these crystals mimic many features of human asthma . The immunological activity is specifically dependent on the crystalline structure, as non-crystallizing mutant forms of GAL10 (particularly those with Tyr69 mutated to glutamic acid) are immunologically inert .

Mechanistically, CLCs promote:

• Dendritic cell uptake and T helper type 2 cell priming

• Airway eosinophilia

• Immunoglobulin G1 (IgG1) responses

• NLRP3 inflammasome activation and interleukin-1β (IL-1β) release, though CLC effects in vivo can occur independently of the NLRP3 inflammasome

Anti-GAL10 antibodies specifically targeting crystal-packing epitopes can effectively dissolve these crystals. The epicenter of crystal-dissolving antibody binding is typically situated at Tyr69, which has been identified as a critical crystal-packing hotspot . These antibodies have demonstrated therapeutic potential by:

• Rapidly dissolving preexisting CLCs both in vitro and in patient mucus samples

• Suppressing airway inflammation

• Reducing goblet-cell metaplasia

• Decreasing bronchial hyperreactivity

• Inhibiting IgE synthesis induced by CLC and house dust mite inhalation in humanized mouse models

This research suggests that targeting GAL10 crystallization with specific antibodies represents a promising therapeutic approach for crystallopathy-associated allergic conditions.

What methodological considerations are important when designing experiments to detect GAL10 in different cell types?

Detection of GAL10 across different cell types requires careful methodological planning:

Flow Cytometry Detection in Regulatory T Cells (Tregs):

• Cell preparation: Expand Tregs from peripheral blood mononuclear cells (PBMCs) using appropriate expansion protocols (e.g., Cloudz Human Treg Expansion Kit)

• Fixation and permeabilization: Use specialized buffers such as FlowX FoxP3/Transcription Factor Fixation & Perm Buffer Kit to access intracellular GAL10

• Staining protocol:

  • Primary staining with anti-GAL10 antibody (e.g., AF5447)

  • Secondary staining with fluorophore-conjugated secondary antibody

  • Co-staining with CD25/IL-2Ra to identify Treg populations

• Controls: Include appropriate isotype controls (e.g., Goat IgG Control Antibody) to establish specific staining thresholds

Western Blot Analysis in Leukemia Cell Lines:

• Sample preparation: Prepare lysates from HL-60 human acute promyelocytic leukemia cells

• Electrophoresis conditions: Use reducing conditions and appropriate buffer systems (e.g., Immunoblot Buffer Group 8)

• Membrane selection: PVDF membranes provide optimal protein binding for GAL10 detection

• Detection sensitivity: Typically visible as a specific band at approximately 16 kDa

• Secondary antibody selection: HRP-conjugated secondary antibodies provide suitable sensitivity

Immunocytochemical Detection:

• Fixation method: Immersion fixation preserves GAL10 epitopes in cultured cells

• Permeabilization: Required to access intracellular GAL10

• Background reduction: Include blocking steps to minimize non-specific binding

• Counterstaining: Consider nuclear counterstains to facilitate cellular localization

When designing multi-parameter experiments, be aware that GAL10 expression can vary significantly between cell types and activation states. For example, GAL10 is detected in specific subsets of immune cells and may require additional markers to correctly identify positive populations.

What are the key considerations for validating GAL10 antibody specificity in experimental systems?

Ensuring GAL10 antibody specificity is critical for generating reliable experimental data:

Cross-Reactivity Testing:

• Perform direct ELISAs against related galectin family members. High-quality GAL10 antibodies should show no cross-reactivity with recombinant human Galectin-1, -2, -3, -4, -7, -8, or -9/Ecalectin

• Test against species homologs if using in cross-species studies, as sequence variations may affect binding

Knockout/Knockdown Controls:

• Include GAL10 knockout or knockdown samples as negative controls

• Verify antibody signal reduction or elimination in these samples to confirm specificity

Multiple Antibody Validation:

• Compare results using antibodies recognizing different epitopes of GAL10

• Concordant results across different antibodies increase confidence in specificity

Epitope Competition Assays:

• Pre-incubate antibodies with recombinant GAL10 protein prior to sample staining

• Specific staining should be blocked by this competition

Immunoprecipitation Validation:

• Perform immunoprecipitation followed by mass spectrometry

• Confirm that precipitated proteins match expected molecular weight and peptide sequences for GAL10

A comprehensive validation approach combining these methods will significantly enhance confidence in experimental findings and reduce the risk of artifactual results when working with GAL10 antibodies.

How can researchers effectively use anti-GAL10 antibodies to investigate the role of GAL10 in allergic and inflammatory diseases?

Anti-GAL10 antibodies offer powerful tools for investigating GAL10's role in disease pathophysiology:

Immunohistochemical Mapping in Patient Samples:

• Examine tissue distribution of crystalline versus soluble GAL10 in patient biopsies

• Correlate GAL10 expression patterns with disease severity markers

• Use dual-staining techniques to identify cell populations expressing GAL10 in affected tissues

Biomarker Development:

• Assess GAL10 levels in sputum samples as a potential biomarker of eosinophilic airway inflammation

• Develop standardized ELISA protocols using validated anti-GAL10 antibodies

• Establish reference ranges and clinical thresholds through comparative studies

Therapeutic Targeting Strategies:

• Screen antibody candidates for their ability to dissolve preformed Charcot-Leyden crystals

• Focus on antibodies targeting the Tyr69 region, which has been identified as a critical crystal-packing hotspot

• Test crystal-dissolving antibodies in humanized mouse models of asthma to assess effects on:

  • Airway inflammation

  • Goblet-cell metaplasia

  • Bronchial hyperreactivity

  • IgE synthesis

Mechanistic Studies:

• Use anti-GAL10 antibodies to neutralize GAL10 function in primary cell cultures

• Investigate downstream signaling effects using phosphoprotein arrays or transcriptomic approaches

• Assess impact on NLRP3 inflammasome activation and IL-1β release

• Examine effects on dendritic cell function and T helper cell polarization

By integrating these approaches, researchers can develop a comprehensive understanding of GAL10's role in disease pathophysiology and establish the foundation for potential therapeutic interventions targeting this protein.

What recent advances have been made in developing antibodies against GAL10, and how might computational approaches enhance future GAL10 antibody design?

Recent advances in GAL10 antibody development reflect broader innovations in antibody engineering:

Therapeutic Anti-GAL10 Antibodies:

• Crystal-dissolving antibodies targeting Tyr69, a critical crystal-packing hotspot in GAL10, have demonstrated promising results in dissolving Charcot-Leyden crystals

• These antibodies have shown efficacy in suppressing airway inflammation, reducing goblet-cell metaplasia, decreasing bronchial hyperreactivity, and inhibiting IgE synthesis in humanized mouse models of asthma

• The mechanism involves disruption of crystal structure rather than simple binding or neutralization of the protein

Computational Antibody Design:
Recent advances in computational antibody design suggest promising approaches for targeting proteins like GAL10 with enhanced precision:

• De novo antibody design without prior antibody information has been demonstrated across multiple target proteins, suggesting applicability to GAL10

• Libraries constructed by combining designed light and heavy chain sequences (10² light chains × 10⁴ heavy chains = 10⁶ total sequences) have successfully yielded specific binders with varying binding strengths

• Computational approaches can potentially generate antibodies with:

  • Precise epitope targeting specificity

  • Ability to distinguish closely related protein subtypes or mutants

  • Optimized affinity and developability characteristics

The integration of atomic-accuracy structure prediction with rational antibody design represents a promising avenue for developing next-generation anti-GAL10 antibodies with enhanced therapeutic potential .

What are the most promising research directions for GAL10 antibodies in the coming years?

Based on current literature and technological trends, several promising research directions for GAL10 antibodies are emerging:

• Therapeutic Development: Further refinement of crystal-dissolving antibodies for clinical applications in asthma and other eosinophilic disorders. This includes optimization of pharmacokinetics, delivery methods, and combination therapies .

• Biomarker Implementation: Validation of standardized assays using anti-GAL10 antibodies for patient stratification in clinical trials and personalized medicine approaches for allergic diseases.

• Structural Biology Integration: Combining X-ray crystallography, cryo-electron microscopy, and computational modeling to design antibodies targeting specific functional domains of GAL10 beyond the crystal-packing interface.

• Expanded Disease Applications: Investigation of GAL10's role in diseases beyond asthma, potentially including other inflammatory and autoimmune conditions where eosinophil function may contribute to pathophysiology.

• Single-Cell Technologies: Application of anti-GAL10 antibodies in single-cell protein profiling to identify novel GAL10-expressing cell populations and their functional significance.